Levetiracetam Amarox

Levetiracetam, the active ingredient in Levetiracetam Amarox, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats partial‑onset seizures, myoclonic seizures, and generalized tonic‑clonic seizures in patients requiring acute seizure control.

GNH USA supplies Levetiracetam Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levetiracetam is an anticonvulsant that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures: reduces seizure frequency and severity in focal epilepsy, improving patient stability. - Myoclonic seizures: controls rapid, involuntary muscle jerks in generalized epilepsy, enhancing daily functioning. - Generalized tonic‑clonic seizures: prevents convulsive episodes in patients with generalized epilepsy, supporting long‑term seizure control.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: transient lightheadedness. - Fatigue: general tiredness. - Irritability: mood changes or agitation. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin and mucous membrane involvement. - Suicidal thoughts: emergence of depressive or suicidal ideation.

When using Levetiracetam Amarox, consider the following precautions.

- Dose adjustment in renal impairment: reduce dose according to creatinine clearance. - Monitor psychiatric status: watch for mood changes or depression. - Avoid abrupt discontinuation: taper gradually to prevent seizure worsening. - Use with caution in patients with hepatic dysfunction: monitor liver function tests. - Pregnancy and lactation: safety not established; evaluate risk‑benefit. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Concomitant use with carbamazepine: may reduce levetiracetam plasma levels. - Co‑administration with enzyme‑inducing antiepileptics (e.g., phenobarbital, phenytoin): may decrease efficacy.

Moderate Interactions (Monitor Closely): - Use with CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Combination with other antiepileptic drugs: monitor seizure control and adjust therapy as needed. - Interaction with renal excretion inhibitors: consider dose adjustment if renal clearance is affected.